13 results about "ErbB" patented technology

To provide: compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK; pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof; and pharmaceutical compositions comprising the compounds.SOLUTION: The invention provides compounds represented by the formula (I), pharmaceutically acceptable salts, esters, hydrates, solvates or stereoisomers thereof.SELECTED DRAWING: None

The application discloses a monoclonal antibody against mouse receptor tyrosine protein kinase Erbb-3 and application thereof. The monoclonal antibody comprises an R138 monoclonal antibody, wherein the light chain CDR1-3 of the R138 antibody are respectively shown as SEQ ID NO. 23-SEQ ID NO. 25, and the heavy chain CDR1-3 are respectively shown as SEQ ID NO. 26-SEQ ID NO. 28. The application further provides a kit comprising the above antibody, which has the advantages of good detection stability, high accuracy, high sensitivity and good specificity, and is suitable for quantitative detection of mouse receptor tyrosine protein kinase Erbb-3 protein.

Provided herein are ex vivo methods of engineering or culturing a submucosal gland (SMG) organoid, comprising isolating submucosal gland basal cells and / or myoepithelial cells (e.g., human cells), and / or submucosal gland stem and / or progenitor cells (e.g., human cells), and culturing such cells with an agonist or ligand of ERBB (e.g., in a three- dimensional matrix). Also provided herein are SMG organoid engineered or cultured ex vivo. Also provided herein are methods of identifying an agent that reduces airway mucus production using an ex vivo SMG organoid described herein. Also provided herein is a method of treating a hypersecretory airway disorder or disease, or a disorder associated with an increased secretion from submucosal glands, in a subject, comprising administering to the subject an agent that inhibits ERBB.

To provide a technique relating to the field of antibodies, in particular a technique relating to the field of therapeutic (human) antibodies for treatment of ErbB-2 / ErbB-3 positive cells, more in particular treatment of cells including an NRG1 fusion gene including at least a portion of the NRG1-gene fused to a sequence derived from a different chromosomal location.SOLUTION: The present invention provides a bispecific antibody that comprises a first antigen-binding site that can bind to an extracellular part of ErbB-2 and a second antigen-binding site that can bind to an extracellular part of ErbB-3 for use in treatment of an individual that has ErbB-2 and ErbB-3 positive cells, the cell including an NRG1 fusion gene including at least a portion of the NRG1 gene fused to a sequence derived from a different chromosomal location.SELECTED DRAWING: None

The present invention relates to the use of nucleotide synthesis pathway inhibitors and macropinocytosis inhibitors for the treatment of tumors. The present disclosure provides the use of nucleotide synthetic pathway inhibitors and macropinocytosis inhibitors in the preparation of medicaments or kits for the treatment of tumors, where the nucleotide synthetic pathway inhibitors may include pyrimidine and / or purine synthetic pathway inhibitors such as orotic dehydrogenase (DHODH) inhibitors and phosphoribose pyrophosphate synthetase 1 (PRPS) inhibitors, the macropinocytosis inhibitor can comprise a macropinocytosis substrate uptake inhibitor, a PAK1 inhibitor, an EGFR signal pathway inhibitor, an ErbB signal pathway inhibitor, an NF-KB signal pathway inhibitor, an EREG inhibitor, a p65 inhibitor and an AREG inhibitor. The invention discloses a new way for activating macropinocytosis by using intracellular signals, provides a new insight for a regulation mechanism in tumor cells, and provides a new method for tumor treatment.

The present invention provides various ADAM17 binding molecules (including antibodies and fragments thereof), compositions comprising such ADAM17 binding molecules, and methods of using such ADAM17 binding molecules and compositions, for example in inhibiting binding of ADAM17 to ADAM17 substrates (such as ErbB ligands), in inhibiting the proliferation of cancer cells, and in treating cancer.

In alternative embodiments, provided are immunohistochemical (IHC) methods and kits for reproducibly determining and scoring the degree of expression of protein tyrosine protein kinase-like 7 (PTK7), also known as colon cancer kinase 4 (CCK4), in a tissue sample; hER2 or a receptor tyrosine protein kinase erbB-2, or a cluster of differentiation 340 (CD340); a programmed death ligand 1 (PD-L1) or a differentiation cluster 274 (CD274); a B7 homolog 1 (B7-H1); and Ki-67 or MKI67 (a proliferation marker Ki-67), as well as a use thereof. In alternative embodiments, methods and kits are provided for diagnosing or selecting an individual eligible for treatment with a cancer or tumor therapeutic agent, or assessing the risk of cancer or tumor recurrence using an IHC method as provided herein. In alternative embodiments, kits comprising components and instructions for performing the methods as provided herein are provided. Described herein are methods for scoring PTK7 expression and utilizing the score as a companion or supplemental diagnosis to help treat or ameliorate cancer or tumor.

Genetically modified non-human animals that express a human or chimeric (e.g., humanized)ERBB, and methods of use thereof are disclosed.

The invention relates to the field of ErbB-2 and / or ErbB3 targeting agents, such as antibodies binding ErbB-2 and / or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2 / ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.

The application belongs to the field of biological medicine, and relates to application of chondroitin acid protein 1 in preparation of a reagent for diagnosing lung adenocarcinoma or evaluating lung adenocarcinoma prognosis. The application screens CRTAC1 from a GEO database through bioinformatics analysis and a machine learning algorithm, and the CRTAC1 is significantly lowly expressed in lung adenocarcinoma tissues, and an AUC reaches 0.972. Verification of a GEPIA database shows that low expression of the CRTAC1 is significantly related to poor prognosis such as advanced pathological stages, and a patient with high expression has better prognosis. The CRTAC1 blocks epithelial-mesenchymal transition through inhibition of an EGF / ErbB signal path, and remodels a tumor immune microenvironment through inhibition of M2 type macrophage polarization. A mouse lung metastasis model proves that overexpression of the CRTAC1 significantly reduces lung metastasis nodules. The application provides a new molecular marker and a drug target for early diagnosis, prognosis evaluation and precise treatment of lung adenocarcinoma.

The disclosure relates to the field of neuregulin-1 (NRG1) fusions, methods for detecting such, identifying or diagnosing patients with such fusions and methods of treatment of a cancer, a tumor or an aberrant cell comprising an NRG1 fusion. Also, it relates to the field of therapeutic (human) compounds for the treatment of subjects with an ErbB-2 / ErbB-3 positive cancer that comprise a NRG1 fusion.

The invention relates to the field of ErbB-2 and / or ErbB3 targeting agents, such as antibodies binding ErbB-2 and / or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2 / ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.

The present invention relates to a method for treating a subject having or at risk of developing breast cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an ErbB-2 / ErbB-3 bispecific antibody in combination with a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that binds to the extracellular portion of ErbB-2 and an antigen binding site that binds to the extracellular portion of ErbB-3; and a device for use in the method.